AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06603857 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: 1927nm (Clear and Brilliant Perméa®)
Description: non-ablative fractional diode laser
Study NCT05134428 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ADAM System
Description: The ADAM System consists of an injectable hydrogel and delivery apparatus that is intended to provide long-lasting, non-permanent vasal occlusion for men, resulting in azoospermia. ADAM is designed to be inserted into the vasa deferentia through a minimally invasive procedure, similar to the no-scalpel vasectomy.
Study NCT06593860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote speech rehabilitation
Description: Two types of intervention will be provided via online to 32 dyads of people with Parkinson's disease: (1) speech therapy (PD patients) and (2) family education/training (PD families). Speech therapy will replicate the dose prescribed by many treatment programs including LSVT LOUD, LSVT ARTIC and Be Clear, consisting of 16 sessions of 50-60 minutes duration delivered over four weeks. Participants will also be set 15 to 20 minutes of daily home practice. Family education/training will take place once a week over 4 weeks.
Study NCT06593678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation Program
Description: Participants in the intervention group will receive a home-based rehabilitation program delivered via an asynchronous digital telerehabilitation platform. The multimodal program is accessible at online platform and it is composed for therapeutic exercises, including aerobic and strength training exercises, aimed at improving functional capacity and quality of life before and after colorectal cancer surgery.
Study NCT06593678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Booklet-based rehabilitation program
Description: Participants in the control group will receive a booklet-based rehabilitation program at home, provided through a detailed printed guide (explanatory booklet). This guide includes instructions in pictures and text for the multimodal program. It is composed for therapeutic exercises, including aerobic and strength training exercises, aimed at improving functional capacity and quality of life before and after colorectal cancer surgery.
Study NCT05078047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced dose intensity of IO
Description: After 6 months of treatment with standard IO, IO will be administered every 3 months (at the same dose levels) until disease progression, unacceptable toxicity, death or patient's choice or investigator's decision
Study NCT06497543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Pemetrexed
Description: Intrathecal pemetrexed(50mg) twice a week for 1 week (day 1 and day 5) as induction treatment, then once monthly until progressive disease.
Study NCT06331819 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: In-lab polysomnography
Description: Patient's brainwaves are recorded overnight to diagnose sleep disorder.
Study NCT06331819 — intervention group
Intervention type: DEVICE
Intervention: Continuous positive airway pressure
Description: A machine that uses air pressure to keep breathing airways open while patients sleep.
Study NCT06331819 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Home sleep study device
Description: Patient's brainwaves are recorded overnight to diagnose sleep disorder.
Study NCT06507774 — intervention group
Intervention type: DEVICE
Intervention: 3D Reconstruction Technology
Description: Utilization of 3D reconstruction technology to assist in preoperative planning and surgical procedures for thoracic surgery patients.
Study NCT06507774 — intervention group
Intervention type: DEVICE
Intervention: No 3D reconstruction is used
Description: This group did not use 3D reconstruction for surgical navigation
Study NCT04684836 — intervention group
Intervention type: OTHER
Intervention: Exposure to telemedicine, after the onset of the pandemic
Description: The exposure of interest was the switch to primary care telemedicine prompted by the COVID-19 epidemic
Study NCT05757284 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lower Limb Lymhedema assessment
Description: assessessment with the selected measurement methods showing sufficient reliability and feasibility in the patient group with LLL from aim 1:NCT05269264. Measurement will occur at the genital/midline region, and on both legs/ feet.
Study NCT06215170 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SafeMedWaste
Description: SafeMedWaste opioid disposal kit
Study NCT04944992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efinopegdutide 20 mg/mL
Description: Subcutaneous injection in a dose-escalation administration of 2.4 mg, 5.0 mg, and 10.0 mg
Study NCT04944992 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide 1.34 mg/mL
Description: Subcutaneous injection in a dose-escalation administration of 0.25 mg, 0.5 mg, and 1.0 mg
Study NCT05148468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active spinal cord stimulation
Description: Spinal cord stimulation is accomplished with surgically implanted epidural leads at Th3 - Th4 levels and a pulse generator implanted in subcutaneous fat. During active stimulation amplitude will be set to 90% paresthesia inducing threshold.
Study NCT05148468 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham spinal cord stimulation
Description: Spinal cord stimulation is accomplished with surgically implanted epidural leads at Th3 - Th4 levels and a pulse generator implanted in subcutaneous fat. During sham stimulation amplitude will be set to zero.
Study NCT06245343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional inspiratory muscle training group
Description: Patients will be given fundamental inspiratory muscle training with the inspiratory muscle training device at 50% of the maximal inspiratory pressure 30 min/day, 3 days/week for 4 weeks online with a physiotherapist. On the other days of the week, the training will be used as a home program.~In the 5th week, the functional inspiratory muscle training program will be started. Before the program begins, patients will be shown the exercises in the functional inspiratory muscle training program. Patients will be given functional inspiratory muscle training with the inspiratory muscle training device at 50% of the maximal inspiratory pressure 30 min/day, 3 days/week for 4 weeks online with a physiotherapist. On the other days of the week, fundamental inspiratory muscle training will be used as a home program.~Pressure increases will be made weekly to 10 centimeters of water (cmH2O). Unsupervised training sessions will be followed by charts filled out by patients.
Study NCT06245343 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: The control group will not be given any training during the 8-week period. After the study, the treatment applied to the training group will also be applied to the control group in order to ensure that the patients in the control group are not ethically deprived of rehabilitation.
Study NCT05816265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Iron Infusion Group
Description: Subjects will receive IV Iron Infusion. Dosage of iron will be at discretion of physicians
Study NCT06245954 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simulated training
Description: Simulation training of bronchoscopists by means of simulators and extracorporeal lungs
Study NCT06245954 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: traditional bedside teaching
Description: TBLC training for bronchoscopists through traditional lectures, hands-on demonstrations
Study NCT06397170 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Graded repetitive arm supplementary program
Description: Patients in Group A will receive Graded repetitive arm supplementary program
Study NCT06397170 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Task based training
Description: Patients in Group B will receive Task based training.
Study NCT05248074 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High-fat meal (over 900 kcal)
Description: High-fat meal (over 900 kcal with over 35 percent fat content of total calorie) will be provided prior to IP administration. The IP will then be administered 30 minutes after the subject begins the meal.
Study NCT05558527 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: social support
Description: social support is provided in the form of social touch (hand holding)
Study NCT05558527 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: social support
Description: social support is provided in the form of social touch (hand holding)
Study NCT06298799 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: DNA Sequencing and Analysis
Description: DNA extracted from saliva / oral mucosa will be tested for diversities reported in the literature known to be associated with T2DM and Obesity and which may have a potential impact on the response to treatment with Semaglutide. In addition, the DNA will be screened for new diversities that have a potential impact on the response to treatment. working assumption of the study is that there can be 3 types of genetic variants that affect the drug's effectiveness and/or side effects.
Study NCT05248074 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: ABN401 (investigational product)
Description: The investigational product, ABN401 800 mg (3 x 250 mg + 2 x 25 mg) will be administered orally with approximately 240 mL of water in fasted or fed condition in accordance with the order of IP administration in an allocated sequence.
Study NCT06298799 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: differential expression analysis with RNA-sequencing (RNA seq) experiments
Description: Performing small RNA sequencing experiments on an Illumina Next-Generation Sequencing (NGS) machine to investigate microRNAs (miRNAs) or other small non-coding RNAs involves specific steps tailored to the unique characteristics of these molecules
Study NCT06314802 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: No intervention
Study NCT04041674 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GEO-D02 DNA
Description: Administered by IM injection into the vastus lateralis
Study NCT05026593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered after completion of Sintilimab by IV infusion to achieve an initial target AUC of 5 mg/mL/min on Day 1.
Study NCT05026593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin will be administered after completion of Sintilimab by IV infusion to achieve an initial target AUC of 5 mg/mL/min on Day 1.
Study NCT05026593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 will be administered after completion of Sintilimab by IV infusion on Day 1.
Study NCT05026593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 will be administered after completion of Sintilimab by IV infusion on Day 1.
Study NCT05026593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide 100 mg/m\^2 will be administered by IV infusion following carboplatin or cisplatin administration, during the induction phase on Day 1 through 3 of each cycle. On Days 2 and 3, patients will receive etoposide alone.
Study NCT05026593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide 100 mg/m\^2 will be administered by IV infusion following carboplatin or cisplatin administration, during the induction phase on Day 1 through 3 of each cycle. On Days 2 and 3, patients will receive etoposide alone.
Study NCT05026593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200 mg will be administered by IV infusion following IBI110 on Day 1 of each 21-day .
Study NCT05026593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab
Description: Sintilimab 200 mg will be administered by IV infusion following IBI110 on Day 1 of each 21-day .
Study NCT05026593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI110
Description: IBI110 RP2D will be administered by IV infusion on Day 1 of each 21-day .
Study NCT04909047 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: parassacral transcutaneous electrostimulation
Description: Use of parassacral transcutaneous electrostimulation
Study NCT05050318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation
Description: Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM)
Study NCT05050318 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation
Description: Suspension for injection in a pre-filled syringe Route of administration: Intramuscular (IM)
Study NCT05800080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy;Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy
Description: one group receives peri operative treatment of Penpulimab combined with Anlotinib Hydrochloride Capsules and chemotherapy, and the other group receives peri operative treatment of Cadonilimab combined with Anlotinib Hydrochloride Capsules and chemotherapy.After receiving corresponding neoadjuvant treatment for 3 cycles according to the established treatment plan, surgical treatment shall be carried out within 3-6 weeks after drug withdrawal
Study NCT05329948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Haptonomy application
Description: Feeling the fetus by touching the mother's womb with meditation
Study NCT06160843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab IV infusion Q3W, with daily oral Olaparib.
Description: Pembrolizumab IV infusion 200 mg Q3W, with daily oral Olaparib 300mg BID, over a 3-week cycle.
Study NCT04041674 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MVA/HIV62B Vaccine
Description: Administered by IM injection into the vastus lateralis
Study NCT04041674 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: B63521^11 gp120
Description: Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose
Study NCT04041674 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IHV01 Protein
Description: Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose
Study NCT05024539 — intervention group
Intervention type: OTHER
Intervention: nonintervention
Study NCT04230629 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vivinex XY1
Description: Implantation of an intraocular lens Hoya Vivinex XY1
Study NCT04230629 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vivinex XY1A
Description: Implantation of an intraocular lens Hoya Vivinex XY1A
Study NCT05247671 — intervention group
Intervention type: GENETIC
Intervention: ERCC1
Description: ERCC1 is a rate-limiting enzyme in the nucleotide excision repair pathway that is known to repair cisplatin-induced DNA damage. Polymorphisms in ERCC1 are known to affect response to cisplatin treatment. A mechanism explaining the effect of the ERCC1 polymorphism on the kidney may be that the homozygous carriers of this rs3212986 allele might have a greater capacity to repair cisplatin-induced DNA damage in their kidney epithelia, and thus would be more resistant to cisplatin-induced nephrotoxicity
Study NCT05247671 — intervention group
Intervention type: GENETIC
Intervention: OCT2
Description: OCT2 is expressed on the basolateral membrane of Proximal Tubular Epithelial Cell (PTEC) and plays a central role in cisplatin uptake into tubular cells. Genetic variants in the cisplatin uptake transporter OCT2 showed association with the preservation of kidney function. Patients with the CT genotype in OCT2 polymorphism rs596881 exhibited positive changes in eGFR compared to individuals with the wild type CC genotype
Study NCT05649215 — intervention group
Intervention type: OTHER
Intervention: No intervention will be applied.
Description: This is a questionnaire study.
Study NCT03110523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X0002
Description: All subjects who provide informed consent will initiate the Screening Period of at least 14 (±3) days for the assessment of eligibility including radiographic evaluation of the lumbar spine. X-ray images must be collected within 4-11 hours after the subject wakes up. Those subjects who meet preliminary eligibility criteria will be treated with placebo in a subject-blind manner for 14(±3) days from Screening Visit to Day 1. Subjects with a placebo response exceeding 25% improvement in the average NPRS score over the previous 7 days will be excluded. Subjects with a Lane grading of 1 or 2 on their neutral lateral lumbar spine film per the central radiologist are eligible to be enrolled. At Day 1, eligible subjects will be randomly assigned to 1 of 2 treatment groups in a 1:1 ratio with a 1:1 ratio of active:placebo within each treatment group, and stratified evenly according to Lane Radiographic Grading Scale summary score (1 or 2) and gender.
Study NCT04041674 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Protein Placebo
Description: Sodium Chloride for Injection, 0.9% USP~Administered as a IM or SC injection into the vastus lateralis or overlying subcutaneous tissue as the MVA dose
Study NCT05490719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: QL1706 is a humanized anti-PD1 IgG4 and anti-CTLA-4 IgG4 antibody.
Study NCT06175806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron Oral Film
Description: 5-hydroxytryptamine (5-HT) receptor antagonist
Study NCT06175806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron Oral Liquid Product
Description: 5-hydroxytryptamine (5-HT) receptor antagonist
Study NCT05101122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dosing 1: Atomoxetine
Description: Oral administration at bedtime
Study NCT05101122 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AD313
Description: Escalating dose of AD313; Oral administration at bedtime
Study NCT05836506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903 Tablet Form 1
Description: Oral Tablets
Study NCT05836506 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-903 Tablet Form 2
Description: Oral Tablets
Study NCT05726305 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Live donor uterus transplantation
Description: Transplantation of uterus from a living donor.
Study NCT05726305 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deceased donor uterus transplantation
Description: Transplantation of uterus from a deceased brain-dead donor.
Study NCT06332599 — intervention group
Intervention type: DRUG
Intervention: BQT
Description: PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, tetracycline 500 mg four times a day, and metronidazole 400 mg four times a day
Study NCT06332599 — intervention group
Intervention type: DRUG
Intervention: PBM4M4
Description: PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg four times a day, and metronidazole 400 mg four times a day
Study NCT06332599 — intervention group
Intervention type: DRUG
Intervention: PBM3M3
Description: PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg three times a day, and metronidazole 400 mg three times a day
Study NCT06332599 — intervention group
Intervention type: DRUG
Intervention: PBM2M4
Description: PPI（esomeprazole or vonoprazan) 20 mg twice daily, bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg twice daily, and metronidazole 400 mg four times a day
Study NCT06332599 — intervention group
Intervention type: DRUG
Intervention: PBM2M3
Description: PPI（esomeprazole or vonoprazan), bismuth potassium citrate 600 mg (220 mg elemental bismuth) twice daily, minocycline 50 mg twice daily, and metronidazole 400 mg three times a day
Study NCT05274815 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tezepelumab
Description: Tezepelumab subcutaneous injection
Study NCT05371717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Domiciliary use of Biorepair Total Protection + Biorepair Shock Treatment
Description: Domiciliary use of Biorepair Total Protection twice a day for oral hygiene + Biorepair Shock Treatment application for 10 min once a day.
Study NCT05371717 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Biorepair Total Protection
Description: Domiciliary use of Biorepair Total Protection twice a day for oral hygiene + Biorepair Shock Treatment application for 10 min once a day.
Study NCT05265429 — intervention group
Intervention type: GENETIC
Intervention: Data and Specimen Collection
Description: * Provide research team access to relevant medical records~* Answer two (2) short questionnaires at time of consent~* Provide up to 5 tubes (37 ml) of blood at or near the time of consent, and/or saliva sample~* Consider consenting to other optional parts of the research such as:~  * Providing additional blood or tissue samples in the future (optional)~ * Providing permission for obtainment of stored tissue specimens from lung cancer surgeries or biopsies from the pathology departments where they have been stored (optional)
Study NCT06533787 — intervention group
Intervention type: DEVICE
Intervention: Echocardiography
Description: Functional echocardiography assessment
Study NCT06030648 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cells (IV-MSC)
Description: Patients will receive 1 infusion (1 x 106 cells/kg on day 0) then be followed for 8 weeks from the infusion.